Analysis of the difference between Inavolisib and Carpiseti

Inavolisib and Capivasertib are two targeted therapies for breast cancer. Although they are both used to treat hormone receptor-positive, HER2-negative breast cancer, there are obvious differences in their mechanisms of action, indications, combination drug strategies, and treatment priorities. This article will analyze in detail the differences between these two drugs.

1. Differences in mechanisms of action

Inalise is a PI3Kδ inhibitor, which mainly controls the growth and survival of tumor cells by inhibiting the PI3Kδ pathway. The PI3K pathway is particularly important in breast cancer cells, especially in patients with PIK3CA gene mutations, where activation of PI3Kδ can promote tumor progression. Inaliset can effectively slow down tumor growth by specifically inhibiting the PI3Kδ isoform.

Carpisetin is an AKT kinase inhibitor that acts downstream of the PI3K signaling pathway. AKT is a key molecule in the PI3K pathway, responsible for regulating cell proliferation, survival and metabolism. Carpisetin blocks cell growth and proliferation by inhibiting the activity of AKT kinase, thereby inhibiting tumor progression.

2. Indications and combination therapy

Inariset is mainly used to treat breast cancer patients with PIK3CA mutations, especially endocrine-resistant hormone receptor-positive, HER2-negative breast cancer. It is often used in combination with palbociclib and fulvestrant and is indicated for patients who have relapsed after or during adjuvant endocrine therapy. By targeting PI3Kδ, inaliside can effectively deal with drug resistance problems caused by PIK3CA mutations.

Carpiseti is used to treat breast cancer patients with PIK3CA, AKT1 or PTEN gene mutations, especially those with metastatic breast cancer who have developed resistance after endocrine therapy. Carpisetin is often used in combination with fulvestrant in patients who have experienced endocrine therapy failure, especially in patients with resistance caused by genetic mutations.

3. Clinical efficacy

Both drugs have demonstrated significant efficacy in the treatment of breast cancer. Inaliset can effectively delay the progression of the disease through combined treatment with palbociclib and fulvestrant, especially in It has shown good efficacy in breast cancer patients with PIK3CA mutations. Inariside has outstanding performance in improving progression-free survival (PFS) and is an important choice for patients who are resistant to endocrine therapy.

Carpiseti can effectively prevent tumor cell proliferation by inhibiting the downstream AKT kinase, especially in breast cancer patients with PIK3CA, AKT1 or PTEN mutations. The advantages of carpiseti in the treatment of metastatic breast cancer are particularly obvious, especially in patients with drug-resistant breast cancer, where it can provide new treatment hope.

4. Side effects and tolerance

Although inaliset and carpisetin are both targeted therapies, they have different side effects. Common side effects of inaliset include rash, diarrhea, fatigue, and decreased appetite, which are usually mild to moderate and can be alleviated by dose adjustment. The side effects of Inaliset are mainly on the skin and digestive system.

The side effects of carpiseti include increased blood sugar, loss of appetite, abnormal liver function, etc. Since capicetine inhibits the AKT kinase downstream of thePI3K pathway, it may have an impact on glucose metabolism and liver function. Therefore, regular monitoring of blood glucose and liver function is required while using carpisetin.

Reference materials:https://www.itovebi-hcp.com/